New publication on Recurrent UTI: Q&A on Clinical Practice1

A novel mode of action to promote antibiotic-sparing approach to Recurrent UTIs: Questions and Answers on Clinical Practice1

Consultations for recurrent urinary tract infections (rUTIs) in everyday clinical practice range from 1% to 6% of all medical visits with high social and personal associated costs, such as prescriptions, hospital expenses, days of sick leave due to the disease, and the treatment of related comorbidities. Often urologists are asked to give practical recommendations to patients regarding the everyday management of recurrent UTIs. A new review1 aims to give to the physicians managing UTI some helpful suggestions for their everyday clinical practice, based on the recent evidence.

Suggestions include, in the era of antibiotic resistance, an antibiotic-sparing approach as an alternative treatment of uncomplicated cystitis in women. Several antibiotic-sparing approaches have been proposed with interesting results. Among them the authors comment a recent meta-analysis2 that demonstrated that a product containing xyloglucan, hibiscus, and propolis is superior to other treatments in terms of clinical effectiveness in women affected by uncomplicated UTI. The authors focused their attention on the promising role of the intestinal barrier in the pathogenesis of gastrointestinal diseases and rUTI as it is well known that uropathogenic Escherichia coli (UPEC) is the most common cause of UTI and the human bowel could be considered as a reservoir of UPEC. In this sense, antibiotic-sparing approaches increasing the mechanical barrier protection, as the xyloglucan-based product, have been recommended for reducing bacteria proliferation and decreasing of the load of UPEC in the bowel and decreasing the bacteria spreading into the perineal area, which undoubtedly implies a novel mode of action in this field.

Utipro® Plus/ Utipro® Plus AF are two medical devices available in the market containing xyloglucan, hibiscus, and propolis.

1 Cai T et al. Recurrent UTI: Questions and Answers on Clinical Practice. Uro 2022, 2, 262–269 (open access paper)

2 Cai, T et al. Xyloglucan, Hibiscus and Propolis in the Management of Uncomplicated Lower Urinary Tract Infections: A Systematic Review and Meta-Analysis. Antibiotics 2021, 11, 14 (open access paper)

Utipro® Plus and Utipro® Plus AF are medical devices intended for the control and prevention of uncomplicated urinary tract infections and comply with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (Utipro® Plus CE 0373, Noventure SL - Utipro® Plus AF CE 0476, Noventure SL)

This information is only intended for Healthcare Professionals.